Some of the factors contributing to the heterogeneity of our cohort include the variety of institutions where patients were treated, the span of the years over which the patients were treated, the relatively small subset of patients with testing for molecular markers, the variety of treatment protocols given to our patients, and the inclusion of IDH1 mutated glioblastomas within our cohort [40]. The gene discussed is IDH1; the disease is glioblastoma.